[go: up one dir, main page]

UY30065A1 - Composiciones farmacéuticas para la erradicación de helicobacter pylori - Google Patents

Composiciones farmacéuticas para la erradicación de helicobacter pylori

Info

Publication number
UY30065A1
UY30065A1 UY30065A UY30065A UY30065A1 UY 30065 A1 UY30065 A1 UY 30065A1 UY 30065 A UY30065 A UY 30065A UY 30065 A UY30065 A UY 30065A UY 30065 A1 UY30065 A1 UY 30065A1
Authority
UY
Uruguay
Prior art keywords
eradication
pharmaceutical compositions
helicobacter pylori
compound
compositions
Prior art date
Application number
UY30065A
Other languages
English (en)
Inventor
Miralles Ricardo
Torres Jesus
Josep M Sune
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of UY30065A1 publication Critical patent/UY30065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición de granulado para la administración oral que comprende simultáneamente un inhibidor de la bomba de protones, un compuesto de claritromicina y un compuesto de amoxicilina. Dichas composiciones son adecuadas para llenarse en sobres y son útiles en el tratamiento de trastornos asociados con la bacteria Helicobacter.
UY30065A 2006-01-03 2006-12-26 Composiciones farmacéuticas para la erradicación de helicobacter pylori UY30065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100029A EP1803450A1 (en) 2006-01-03 2006-01-03 Pharmaceutical compositions for the eradication of helicobacter pylori

Publications (1)

Publication Number Publication Date
UY30065A1 true UY30065A1 (es) 2007-04-30

Family

ID=36587265

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30065A UY30065A1 (es) 2006-01-03 2006-12-26 Composiciones farmacéuticas para la erradicación de helicobacter pylori

Country Status (6)

Country Link
EP (1) EP1803450A1 (es)
AR (1) AR058739A1 (es)
PE (1) PE20071174A1 (es)
TW (1) TW200744676A (es)
UY (1) UY30065A1 (es)
WO (1) WO2007077158A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722039A3 (en) * 2007-11-12 2014-08-13 Pharmaceutics International, Inc. Tri-molecular complexes and their use in drug delivery systems
RU2403904C1 (ru) * 2009-02-26 2010-11-20 Федеральное государственное учреждение "Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Росздрава" Способ профилактики острых гастродуоденальных язв у больных колоректальным раком в раннем послеоперационном периоде
IT1400415B1 (it) 2010-05-26 2013-05-31 Over S R L Composizioni per il trattamento della infezione da helicobacter pylori.
CA2900763C (en) * 2013-02-13 2021-04-06 Reza Fathi Pharmaceutical compositions for the treatment of helicobacter pylori
BR202014031413U2 (pt) * 2014-12-15 2016-06-21 Ems Sa kit para administração conjunta de medicamentos
CN104940170A (zh) * 2015-07-23 2015-09-30 浙江亚太药业股份有限公司 一种埃索美拉唑镁肠溶胶囊及其制备方法
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6576625B2 (en) 2001-03-16 2003-06-10 Panacea Biotic Limited Targeted vesicular constructs for cytoprotection and treatment of H. pylori infections
US20050163857A1 (en) 2002-04-03 2005-07-28 Ashok Rampal Clarithromycin formulations having improved bioavailability
EP1492504A2 (en) 2002-04-03 2005-01-05 Ranbaxy Laboratories, Ltd. Taste masked compositions of erythromycin a and derivatives thereof
US20040180935A1 (en) 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
KR100581967B1 (ko) * 2003-12-18 2006-05-22 한국유나이티드제약 주식회사 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
WO2005082331A2 (en) 2004-02-26 2005-09-09 Ranbaxy Laboratories Limited Extended release tablets of clarithromycin

Also Published As

Publication number Publication date
EP1803450A1 (en) 2007-07-04
TW200744676A (en) 2007-12-16
PE20071174A1 (es) 2007-11-23
WO2007077158A1 (en) 2007-07-12
AR058739A1 (es) 2008-02-20

Similar Documents

Publication Publication Date Title
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
CO6341541A2 (es) Composiciones para el cuidado oral que comprenden capsulas
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
AR051397A1 (es) Composicion farmaceutica
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
CY1113141T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
WO2007064885A3 (en) Oral care compositions, methods, devices and systems
CR11418A (es) Trans-clomifeno para el sindrome metabolico
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
AR109263A2 (es) Composición que comprende moxidectina
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
EA201170512A1 (ru) Композиция для перорального введения
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
PA8571901A1 (es) Nueva composicion farmaceutica
UY30065A1 (es) Composiciones farmacéuticas para la erradicación de helicobacter pylori
BRPI0620229A8 (pt) formulação
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
GT200800208A (es) Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
AR067351A1 (es) Combinacion de picotamida con nafronil